glp-1 obesity drug updates Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine The GLP-1 Access Gap: Mapping

So far, so good

doi:10.1007/s11064-017-2250-8 191

Very recently, GLP1 monotherapies have also been applied in the pharmacological management of PCOS, with promising results 32 , which are yet to be consolidated in clinical practice

The GLP-1 component is responsible for many of the medication's beneficial effects, including enhanced insulin secretion, reduced glucagon release, delayed gastric emptying, and appetite suppression

By balancing the potential benefits and risks of treatment using evidence-based strategies, HCPs are well placed to help optimise the use of GLP-1 RAs in the management of obesity and overweight